(BSX) is down at $28.32 Boston Scientific To Participate In…

Remigio Civitarese
Novembre 14, 2017

Toronto Dominion Bank lifted its stake in Boston Scientific Corporation (NYSE:BSX) by 12.2% in the 3rd quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 520,365 shares of the medical equipment provider's stock after purchasing an additional 56,539 shares during the quarter.

Other large investors also recently bought and sold shares of the company. As of the end of the quarter American International Group Inc had disposed of 21,527 shares trimming its stake by 5.0%. Bank of Montreal Can now owns 576,861 shares of the medical equipment provider's stock worth $15,990,000 after buying an additional 65,725 shares during the period.

For this year, Boston Scientific Corporation (NYSE:BSX) is performing 31.53%. Winslow Capital Management LLC now owns 11,212,783 shares of the medical equipment provider's stock valued at $310,818,000 after buying an additional 2,011,640 shares during the period.

Needle moving action has been spotted in Applied Optoelect (AAOI) as shares are moving today on volatility -2.34% or -1.06 from the open. Louisiana State Employees Retirement System now owns 84,900 shares of the medical equipment provider's stock worth $2,353,000 after purchasing an additional 1,100 shares during the last quarter. Value investors will surely go for the low or decreasing P/FCF totals and reasonably low stock share prices. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, EVP Timothy A. Pratt sold 10,104 shares of the company's stock in a transaction on Friday, September 1st. Moving averages are considered to be lagging indicators that simply take the average price of a stock over a specific period of time. Following the completion of the transaction, the senior vice president now owns 12,615 shares of the company's stock, valued at approximately $301,498.50. Insiders own 1.31% of the company's stock. The first sale was made at $28.5 but later the stock became weaker, and closed with a fall of -0.8%. The overall volume in the last trading session was 4.72 million shares.

The company now has an insider ownership of 0.1 Percent and Institutional ownership of 94.2 Percent. UBS AG restated a "buy" rating and issued a $31.00 price target (up from $30.00) on shares of Boston Scientific Corporation in a research note on Tuesday, August 1st. In the latest earnings report the EPS was $0.61 with 1.37B shares now outstanding. Boston Scientific Corporation had a net margin of 9.55% and a return on equity of 23.60%. The 1 year EPS growth rate is 27.10%. The company's revenue for the quarter was up 5.6% compared to the same quarter previous year. If you are reading this piece on another domain, it was stolen and reposted in violation of USA and worldwide trademark and copyright law. If you are viewing this report on another site, it was stolen and reposted in violation of United States and global trademark and copyright law. The 14-day ADX for Boston Scientific Corp (BSX) is now at 36.04.

BSX has been the subject of several research reports. Finally, Wedbush upped their price target on shares of Boston Scientific Corp. from $23.00 to $25.00 and gave the company a neutral rating in a report on Friday, July 29th. On October 31, 2017 SunTrust Banks updated guidance on BSX with a rating of "Buy" and projecting a price target of $34.00. Canaccord Genuity issued a report on BSX setting a rating of "Buy". The company has an average rating of "Buy" and an average target price of $30.77.

Boston Scientific Corporation, launched on June 22, 1979, is a developer, manufacturer and marketer of medical devices that are used in a range of interventional medical specialties. The Company offers its products by seven core businesses: Interventional Cardiology, Peripheral Interventions (PI), Cardiac Rhythm Management (CRM), Electrophysiology (EP), Endoscopy, Urology and Pelvic Health, and Neuromodulation.

Altre relazioniGrafFiotech

Discuti questo articolo

Segui i nostri GIORNALE